In the last years, neuroprotective therapies have attracted the researcher interests as
modern and challenging approach for the treatment of neurodegenerative diseases, aimed …

Glaucoma is the world's leading irreversible blinding eye disease. Lowering intraocular
pressure is currently the only effective clinical treatment. However, there is a lack of long …

The therapeutic value of microRNA (miRNA) for the treatment of glaucoma has become a
focus of attention. However, naked miRNA cannot cross the corneal barrier and reach the …

Glaucoma is a neurodegenerative eye disease that causes permanent vision impairment.
The main pathological characteristics of glaucoma are retinal ganglion cell (RGC) loss and …

Ocular devices worn on human eyeballs with hemispherical appearance and intelligent
functionals are expected to perform continuous and nondestructive oculopathy disease …

Transfection of functional genetic molecules into neuroma cells to efficiently manipulate
gene expression is of great significance in neuro-associated gene therapy. However, most …

Background Genomic research advances the understanding of human health and disease. It
also drives both the discovery of salient genetic association (s) as well as targeted …

Editorial: Ocular Drug delivery - Challenges, Opportunities, and Developments Editorial:
Ocular Drug delivery - Challenges, Opportunities, and Developments Adv Drug Deliv Rev …

An elevation of pathologic intraocular pressure (IOP) is the greatest risk factor for glaucoma.
CD154 has been reported to bind to CD40 expressed by orbital fibroblasts and be involved …

Elevated intraocular pressure (IOP) in glaucoma causes retinal ganglion cell (RGC) loss and
damage to the optic nerve. Although IOP is controlled pharmacologically, no treatment is …